** Shares of therapy developer Marinus Pharmaceuticals
fall ~61.5% to 65 cents premarket
** Co says it is discontinuing development of its oral drug ganaxolone after it missed the main goal in a late-stage trial in patients with a rare genetic brain disease called tuberous sclerosis complex (TSC)
** MRNS says the drug did not show a significant reduction in frequency of TSC-associated seizures
** Co says it is exploring strategic alternatives and is taking additional steps to reduce costs, including a reduction in its workforce
** Up to last close, stock down 84.5% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。